CN104822699B - 用于治疗肥胖症的胰高血糖素/glp-1激动剂 - Google Patents

用于治疗肥胖症的胰高血糖素/glp-1激动剂 Download PDF

Info

Publication number
CN104822699B
CN104822699B CN201380062842.3A CN201380062842A CN104822699B CN 104822699 B CN104822699 B CN 104822699B CN 201380062842 A CN201380062842 A CN 201380062842A CN 104822699 B CN104822699 B CN 104822699B
Authority
CN
China
Prior art keywords
glp
less
peptide
glucagon
agonist peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380062842.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN104822699A (zh
Inventor
B·阿格拉姆
M·安童森
M·贝德纳瑞克
N·伯迈斯特
L·班瑟姆
D·费尔曼
M·弗里齐-弗雷丁
R·杰克逊
R·J·洛夫马克
J·梅特卡夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune LLC
Original Assignee
MedImmune LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune LLC filed Critical MedImmune LLC
Priority to CN201910117184.2A priority Critical patent/CN109776670A/zh
Publication of CN104822699A publication Critical patent/CN104822699A/zh
Application granted granted Critical
Publication of CN104822699B publication Critical patent/CN104822699B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Child & Adolescent Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
CN201380062842.3A 2012-12-11 2013-12-10 用于治疗肥胖症的胰高血糖素/glp-1激动剂 Active CN104822699B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910117184.2A CN109776670A (zh) 2012-12-11 2013-12-10 用于治疗肥胖症的胰高血糖素/glp-1激动剂

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261735823P 2012-12-11 2012-12-11
US61/735,823 2012-12-11
PCT/IB2013/003191 WO2014091316A2 (en) 2012-12-11 2013-12-10 Glucagon/glp-1 agonists for the treatment of obesity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201910117184.2A Division CN109776670A (zh) 2012-12-11 2013-12-10 用于治疗肥胖症的胰高血糖素/glp-1激动剂

Publications (2)

Publication Number Publication Date
CN104822699A CN104822699A (zh) 2015-08-05
CN104822699B true CN104822699B (zh) 2019-03-01

Family

ID=50588751

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201910117184.2A Pending CN109776670A (zh) 2012-12-11 2013-12-10 用于治疗肥胖症的胰高血糖素/glp-1激动剂
CN201380062842.3A Active CN104822699B (zh) 2012-12-11 2013-12-10 用于治疗肥胖症的胰高血糖素/glp-1激动剂

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201910117184.2A Pending CN109776670A (zh) 2012-12-11 2013-12-10 用于治疗肥胖症的胰高血糖素/glp-1激动剂

Country Status (26)

Country Link
US (4) US9765130B2 (enExample)
EP (2) EP3495380B1 (enExample)
JP (1) JP6490011B2 (enExample)
KR (1) KR102080366B1 (enExample)
CN (2) CN109776670A (enExample)
AR (1) AR093903A1 (enExample)
AU (3) AU2013356934C1 (enExample)
BR (1) BR112015012238B1 (enExample)
CA (1) CA2893445C (enExample)
CY (2) CY1121114T1 (enExample)
DK (2) DK2931745T3 (enExample)
ES (2) ES2926713T3 (enExample)
HR (2) HRP20181678T1 (enExample)
HU (1) HUE039952T2 (enExample)
LT (2) LT2931745T (enExample)
MX (2) MX365458B (enExample)
PL (2) PL2931745T3 (enExample)
PT (2) PT2931745T (enExample)
RS (2) RS57899B1 (enExample)
RU (2) RU2018137842A (enExample)
SG (2) SG11201503230XA (enExample)
SI (2) SI3495380T1 (enExample)
SM (2) SMT202200266T1 (enExample)
TR (1) TR201815172T4 (enExample)
TW (2) TWI674270B (enExample)
WO (1) WO2014091316A2 (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
TWI674270B (zh) * 2012-12-11 2019-10-11 英商梅迪繆思有限公司 用於治療肥胖之升糖素與glp-1共促效劑
MX362190B (es) 2012-12-21 2019-01-08 Sanofi Sa Agonistas duales de glp1/gip o trigonales de glp1/gip/glucagon.
AU2014230472A1 (en) * 2013-03-14 2015-10-01 Medimmune Limited Pegylated glucagon and GLP-1 co-agonists for the treatment of obesity
WO2015086729A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/gip receptor agonists
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
TW201609796A (zh) 2013-12-13 2016-03-16 賽諾菲公司 非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
CN106519015B (zh) * 2014-09-23 2020-04-17 深圳市图微安创科技开发有限公司 胃泌酸调节素类似物
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
WO2016198624A1 (en) 2015-06-12 2016-12-15 Sanofi Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
WO2016198628A1 (en) 2015-06-12 2016-12-15 Sanofi Non-acylated exendin-4 derivatives as dual glp-1/glucagon receptor agonists
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
TWI622596B (zh) * 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
CN113546159B (zh) * 2015-12-29 2023-09-08 派格生物医药(苏州)股份有限公司 包含glp-1受体激动剂和胰高血糖素受体激动剂的组合物及其用途
KR102460198B1 (ko) * 2016-03-10 2022-10-31 메디뮨 리미티드 비만 치료를 위한 글루카곤 및 glp-1 공동-작용제
WO2017210099A1 (en) * 2016-06-02 2017-12-07 Indiana University Research And Technology Corporation Glucagon-t3 conjugates
CN107281471A (zh) * 2017-06-26 2017-10-24 中国药科大学 一种改构的胰高血糖素样肽－1及其修饰物的应用
CN111278853B (zh) * 2017-11-06 2022-06-21 深圳市图微安创科技开发有限公司 基于胃泌酸调节素类似物glp-1r/gcgr双靶点激动剂多肽治疗胆汁性肝硬化
TWI770085B (zh) * 2017-11-21 2022-07-11 日商武田藥品工業股份有限公司 胜肽化合物
DK3774862T3 (da) 2018-04-05 2022-09-05 Sun Pharmaceutical Ind Ltd Nye GLP-1-analoger
CN111171134B (zh) * 2018-11-12 2023-08-15 天津药物研究院有限公司 胰高血糖素衍生肽及其用途
JP2022533674A (ja) 2019-05-21 2022-07-25 メディミューン リミテッド シクロデキストリンをベースとするｓｇｌｔ２阻害剤及びインクレチンペプチドの注射用共製剤
JP2022539200A (ja) 2019-07-01 2022-09-07 メドイミューン・リミテッド グルカゴン及びｇｌｐ－１コアゴニストペプチドのための医薬組成物
CN110845601B (zh) * 2019-10-12 2021-01-19 广东药科大学 不同构型的glp-1类似肽修饰二聚体及其制备方法在治疗ii型糖尿病中的应用
KR20220110506A (ko) * 2019-12-03 2022-08-08 메디뮨 엘엘씨 비만 치료를 위한 글루카곤 및 glp-1 공동-작용제를 사용하는 조합 치료법
TW202140061A (zh) 2020-01-10 2021-11-01 英商梅迪繆思有限公司 用於治療２型糖尿病中的慢性腎病和糖尿病性腎病的升糖素及ｇｌｐ－１協同促效劑
CN113493503B (zh) * 2020-04-08 2022-08-05 浙江道尔生物科技有限公司 一种肠促胰岛素类似物及其制备方法和用途
CN120737188A (zh) 2020-04-24 2025-10-03 勃林格殷格翰国际有限公司 作为长效glp-1/升糖素受体激动剂以治疗脂肪肝疾病及脂肪肝炎的升糖素类似物
TW202313974A (zh) 2021-06-08 2023-04-01 瑞典商阿斯特捷利康公司 用於治療肝病之組合療法
CA3226846A1 (en) 2021-07-30 2023-02-02 Boehringer Ingelheim International Gmbh Dose regimen for long-acting glp1/glucagon receptor agonists
TW202346323A (zh) 2022-02-07 2023-12-01 英商梅迪繆思有限公司 具有改善的生物穩定性的ｇｌｐ—１及升糖素雙重激動肽
EP4611736A1 (en) * 2022-11-03 2025-09-10 Efil Bioscience Inc. Composition comprising glp-1 receptor agonist and acat inhibitor
WO2024123812A1 (en) * 2022-12-05 2024-06-13 Shattuck Labs, Inc. Fusion proteins for the treatment of cardiometabolic diseases
WO2024165571A2 (en) 2023-02-06 2024-08-15 E-Therapeutics Plc Inhibitors of expression and/or function
CN115975057B (zh) * 2023-03-16 2023-05-16 杭州信海医药科技有限公司 一种可妥度肽的固相合成方法
WO2024252366A1 (en) 2023-06-09 2024-12-12 Sun Pharmaceutical Industries Limited Glp-1/gip dual, glp-1/gcg dual and glp-1/gip/gcg triple receptor agonists
WO2025024788A1 (en) * 2023-07-27 2025-01-30 Biomedit, Llc Stabilized glp-1 peptides and dual agonist peptides against glp-1r and gipr and methods of use thereof
WO2025125576A2 (en) 2023-12-15 2025-06-19 E-Therapeutics Plc Inhibitors of expression and/or function
WO2025133348A1 (en) 2023-12-22 2025-06-26 E-Therapeutics Plc Inhibitors of expression and/or function
WO2025196502A1 (en) 2024-03-20 2025-09-25 North Carolina Agricultural & Technical State University Choline kinase inhibitors as a therapeutic treatment for obesity
WO2025242620A1 (en) 2024-05-20 2025-11-27 Medimmune Limited Polypeptide combinations and uses thereof
CN118787658B (zh) * 2024-06-14 2025-01-21 中国农业大学 一种胰高血糖素样肽-1受体特异性核酸适配体在代谢疾病干预中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004022004A2 (en) * 2002-09-06 2004-03-18 Bayer Pharmaceuticals Corporation Modified glp-1 receptor agonists and their pharmacological methods of use
CN1935846A (zh) * 2005-09-14 2007-03-28 王庆华 一种用于治疗糖尿病的融合蛋白及其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US30326A (en) * 1860-10-09 Steam-g-eneratob
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
CA2006596C (en) 1988-12-22 2000-09-05 Rika Ishikawa Chemically-modified g-csf
CN1938334A (zh) * 2004-01-30 2007-03-28 瓦拉塔药品公司 Glp－1激动剂和胃泌素化合物的联合使用
DE102004043153B4 (de) * 2004-09-03 2013-11-21 Philipps-Universität Marburg Erfindung betreffend GLP-1 und Exendin
MX2008002028A (es) * 2005-08-11 2008-03-27 Amylin Pharmaceuticals Inc Polipeptidos hibridos con propiedades de seleccion.
PL2173890T3 (pl) 2007-06-21 2011-07-29 Univ Muenchen Tech Białka czynne biologicznie o zwiększonej stabilności in vivo i (lub) in vitro
WO2009058734A1 (en) * 2007-10-30 2009-05-07 Indiana University Research And Technology Corporation Compounds exhibiting glucagon antagonist and glp-1 agonist activity
BRPI1014508A2 (pt) 2009-06-16 2016-04-05 Univ Indiana Res & Tech Corp análogos de peptídeo de glucagon, dimer de dois peptídeos de glucagon, composição farmacêutica deles derivada e métodos para seu uso"
JP6121323B2 (ja) * 2010-05-13 2017-05-10 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ 核内ホルモン受容体の活性を示すグルカゴンスーパーファミリーのペプチド
TWI674270B (zh) * 2012-12-11 2019-10-11 英商梅迪繆思有限公司 用於治療肥胖之升糖素與glp-1共促效劑

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004022004A2 (en) * 2002-09-06 2004-03-18 Bayer Pharmaceuticals Corporation Modified glp-1 receptor agonists and their pharmacological methods of use
CN1935846A (zh) * 2005-09-14 2007-03-28 王庆华 一种用于治疗糖尿病的融合蛋白及其制备方法和应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Glucagon and Glucagon-like Peptide 1: Selective Receptor Recognition via Distinct Peptide Epitopes;Hjorth.S.A等;《The Journal of Biological Chemistry》;19940101;第269卷(第48期);摘要，表1 *

Also Published As

Publication number Publication date
US9765130B2 (en) 2017-09-19
HUE039952T2 (hu) 2019-02-28
EP2931745A2 (en) 2015-10-21
US20200115431A1 (en) 2020-04-16
EP3495380B1 (en) 2022-03-30
TWI617574B (zh) 2018-03-11
DK3495380T3 (da) 2022-06-20
CY1121114T1 (el) 2019-12-11
CN109776670A (zh) 2019-05-21
MX365458B (es) 2019-06-04
AU2013356934A1 (en) 2015-05-21
CN104822699A (zh) 2015-08-05
CA2893445A1 (en) 2014-06-19
TWI674270B (zh) 2019-10-11
HK1216179A1 (en) 2016-10-21
TW201427993A (zh) 2014-07-16
PL3495380T3 (pl) 2022-08-01
AR093903A1 (es) 2015-06-24
KR102080366B1 (ko) 2020-02-21
MX2015006568A (es) 2015-08-05
CA2893445C (en) 2020-06-02
EP3495380A1 (en) 2019-06-12
US10556939B2 (en) 2020-02-11
JP2016501256A (ja) 2016-01-18
RU2015127780A (ru) 2017-01-19
US20170342121A1 (en) 2017-11-30
PT2931745T (pt) 2018-11-29
SMT202200266T1 (it) 2022-07-21
TW201829452A (zh) 2018-08-16
PT3495380T (pt) 2022-06-28
AU2019272054A1 (en) 2020-01-02
US20150307579A1 (en) 2015-10-29
WO2014091316A2 (en) 2014-06-19
SI3495380T1 (sl) 2022-08-31
WO2014091316A3 (en) 2014-10-30
SI2931745T1 (sl) 2018-11-30
MX2019006260A (es) 2019-08-14
KR20150093167A (ko) 2015-08-17
RU2671088C2 (ru) 2018-10-29
TR201815172T4 (tr) 2018-11-21
RU2018137842A (ru) 2018-12-13
US20220098265A1 (en) 2022-03-31
BR112015012238A2 (enExample) 2017-08-15
RS57899B1 (sr) 2019-01-31
AU2017261505C1 (en) 2020-07-30
SMT201800611T1 (it) 2019-01-11
HRP20181678T1 (hr) 2019-03-08
SG11201503230XA (en) 2015-06-29
AU2017261505B2 (en) 2019-10-10
AU2013356934C1 (en) 2018-07-05
MX388904B (es) 2025-03-20
AU2013356934B2 (en) 2017-08-17
LT3495380T (lt) 2022-06-27
PL2931745T3 (pl) 2019-04-30
RS63305B1 (sr) 2022-07-29
BR112015012238B1 (pt) 2022-03-29
JP6490011B2 (ja) 2019-03-27
US11230584B2 (en) 2022-01-25
SG10201801159WA (en) 2018-03-28
AU2017261505A1 (en) 2017-12-07
ES2698329T3 (es) 2019-02-04
ES2926713T3 (es) 2022-10-27
LT2931745T (lt) 2018-11-12
CY1125302T1 (el) 2025-03-28
EP2931745B1 (en) 2018-08-22
RU2018137842A3 (enExample) 2022-04-01
DK2931745T3 (en) 2018-12-10
HRP20220734T1 (hr) 2022-09-02

Similar Documents

Publication Publication Date Title
CN104822699B (zh) 用于治疗肥胖症的胰高血糖素/glp-1激动剂
JP5887335B2 (ja) 新規ペプチドならびにそれらを調製および使用するための方法
US9714277B2 (en) Pegylated glucagon and GLP-1 co-agonists for the treatment of obesity
KR102460198B1 (ko) 비만 치료를 위한 글루카곤 및 glp-1 공동-작용제
CN103649127A (zh) 用于代谢病症和疾病治疗的组合物、应用和方法
WO2008018600A1 (fr) AGENT THÉRAPEUTIQUE PERMETTANT D'ACCÉLÉRER LA RÉPARATION DES NERFS RACHIDIENS COMPRENANT EN TANT QUE MATIÈRE ACTIVE DE LA GHRÉLINE, UN DÉRIVÉ DE CELLE-CI OU UNE SUBSTANCE CAPABLE D'AGIR SUR LE GHS-R1a
WO2017197048A1 (en) Albumin binding conjugate compositions and methods of making and using same
HK40010017B (en) Glucagon and glp-1 co-agonists for the treatment of obesity
BR122017013755A2 (pt) peptideos agonistas de glucagon/glp-1, composição farmaceutica, kit e uso compreendendo tais peptídeos

Legal Events

Date Code Title Description
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant